{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:04:58Z","timestamp":1777899898021,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":140,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_2","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"31-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Update on Antiretroviral Therapy"],"prefix":"10.1007","author":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samara","family":"Mart\u00edn-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrella","family":"Frutos-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","volume":"234","author":"L Men\u00e9ndez-Arias","year":"2017","unstructured":"Men\u00e9ndez-Arias L, Sebasti\u00e1n-Mart\u00edn A, \u00c1lvarez M (2017) Viral reverse transcriptases. Virus Res 234:153\u2013176","journal-title":"Virus Res"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000331993","volume":"55","author":"J Eberle","year":"2012","unstructured":"Eberle J, G\u00fcrtler L (2012) HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology 55:79\u201383","journal-title":"Intervirology"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12977-019-0504-z","volume":"16","author":"PV Afonso","year":"2019","unstructured":"Afonso PV, Cassar O, Gessain A (2019) Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes. Retrovirology 16:39","journal-title":"Retrovirology"},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3390\/v3071074","volume":"3","author":"R Mahieux","year":"2011","unstructured":"Mahieux R, Gessain A (2011) HTLV-3\/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects. Viruses 3:1074\u20131090","journal-title":"Viruses"},{"key":"2_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12977-017-0379-9","volume":"14","author":"DM Pinto-Santini","year":"2017","unstructured":"Pinto-Santini DM, Stenbak CR, Linial ML (2017) Foamy virus zoonotic infections. Retrovirology 14:55","journal-title":"Retrovirology"},{"key":"2_CR6","unstructured":"UNAIDS (2020) Global factsheets. World Health Organization, Geneva. http:\/\/aidsinfor.unaids.org. Accessed 30 Oct 2020"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-019-1200-9","volume":"570","author":"L Dwyer-Lindgren","year":"2019","unstructured":"Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, Mayala BK, VanderHeide JD, Collison ML, Hall JB et al (2019) Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature 570:189\u2013193","journal-title":"Nature"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/COH.0000000000000588","volume":"15","author":"N Phanuphak","year":"2020","unstructured":"Phanuphak N, Gulick RM (2020) HIV treatment and prevention 2019: current standards of care. Curr Opin HIV AIDS 15:4\u201312","journal-title":"Curr Opin HIV AIDS"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0165-6147(02)02054-0","volume":"23","author":"L Men\u00e9ndez-Arias","year":"2002","unstructured":"Men\u00e9ndez-Arias L (2002) Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23:381\u2013388","journal-title":"Trends Pharmacol Sci"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-Arias","year":"2013","unstructured":"Men\u00e9ndez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98:93\u2013120","journal-title":"Antiviral Res"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1074\/jbc.REV119.006901","volume":"294","author":"AN Engelman","year":"2019","unstructured":"Engelman AN (2019) Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition. J Biol Chem 294:15137\u201315157","journal-title":"J Biol Chem"},{"key":"2_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tips.2007.10.013","volume":"29","author":"L Men\u00e9ndez-Arias","year":"2008","unstructured":"Men\u00e9ndez-Arias L, T\u00f6zs\u00e9r J (2008) HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci 29:42\u201349","journal-title":"Trends Pharmacol Sci"},{"key":"2_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097482","volume":"9","author":"FJ Lee","year":"2014","unstructured":"Lee FJ, Amin J, Carr A (2014) Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks\u2019 follow-up. PLoS One 9:e97482","journal-title":"PLoS One"},{"key":"2_CR14","unstructured":"European AIDS Clinical Society (EACS) (2019) European guidelines for treatment of HIV-positive adults in Europe:2018., version 9.1. http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf. Accessed 30 October 2020"},{"key":"2_CR15","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2019) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services (12\/18\/19). https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0. Accessed 30 Oct 2020"},{"key":"2_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP et al (2018) Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA 320:379\u2013396","journal-title":"JAMA"},{"key":"2_CR17","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D et al (2017) Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 390:2063\u20132072","journal-title":"Lancet"},{"key":"2_CR18","doi-asserted-by":"crossref","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J et al (2017) Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 390:2073-2082","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Dolutegravir\/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs 80:61\u201372","journal-title":"Drugs"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, J\u00e4gel-Guedes E, Rugina S, Kozyrev O, Cid JF et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568\u2013579","journal-title":"N Engl J Med"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jac\/dkn292","volume":"62","author":"J Borr\u00e1s-Blasco","year":"2008","unstructured":"Borr\u00e1s-Blasco J, Navarro-Ruiz A, Borr\u00e1s C, Caster\u00e1 E (2008) Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 62:879\u2013888","journal-title":"J Antimicrob Chemother"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","volume":"93","author":"X Tao","year":"2020","unstructured":"Tao X, Lu Y, Zhou Y, Zhang L, Chen Y (2020) Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis 93:108\u2013117","journal-title":"Int J Infect Dis"},{"key":"2_CR23","doi-asserted-by":"publisher","first-page":"104614","DOI":"10.1016\/j.antiviral.2019.104614","volume":"171","author":"JR Beadle","year":"2019","unstructured":"Beadle JR, Aldern KA, Zhang XQ, Valiaeva N, Hostetler KY, Schooley RT (2019) Octadecyloxyethyl benzyl tenofovir: a novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate. Antiviral Res 171:104614","journal-title":"Antiviral Res"},{"key":"2_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/jac\/dkv183","volume":"70","author":"N Apostolova","year":"2015","unstructured":"Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother 70:2693\u20132708","journal-title":"J Antimicrob Chemother"},{"key":"2_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N et al (2019) Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 381:803\u2013815","journal-title":"N Engl J Med"},{"key":"2_CR26","doi-asserted-by":"crossref","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC et al (2020) Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials. Clin Infect Dis 71:1379-1389","DOI":"10.1093\/cid\/ciz999"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/v1031137","volume":"1","author":"L Men\u00e9ndez-Arias","year":"2009","unstructured":"Men\u00e9ndez-Arias L (2009) Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses 1:1137\u20131165","journal-title":"Viruses"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582\u20131586","journal-title":"Science"},{"key":"2_CR29","volume-title":"The HIV & hepatitis drug resistance and pk guide","author":"B Clotet","year":"2017","unstructured":"Clotet B, Men\u00e9ndez-Arias L, Schapiro JM, Kuritzkes D, Burger D, Rockstroh J, Boucher CA, Richman DD, Paredes R (2017) The HIV & hepatitis drug resistance and pk guide, 16th edn. Fundaci\u00f3 de Lluita contra la SIDA, Barcelona","edition":"16"},{"key":"2_CR30","first-page":"111","volume":"27","author":"AM Wensing","year":"2019","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard HF, Paredes R, Shafer RW, Richman DD (2019) 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med 27:111\u2013121","journal-title":"Top Antivir Med"},{"key":"2_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","volume":"102","author":"L Men\u00e9ndez-Arias","year":"2014","unstructured":"Men\u00e9ndez-Arias L, Alvarez M (2014) Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 102:70\u201386","journal-title":"Antiviral Res"},{"key":"2_CR32","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","volume":"1","author":"MC Puertas","year":"2020","unstructured":"Puertas MC, Ploumidis G, Ploumidis M, Fumero E, Clotet B, Walworth CM, Petropoulos CJ, Martinez-Picado J (2020) Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe 1:e130\u2013e135","journal-title":"Lancet Microbe"},{"issue":"Suppl 1","key":"2_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/hiv.12236","volume":"16","author":"JD Baxter","year":"2015","unstructured":"Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, Johnson MA, Jacoby S, Llibre JM, Lundgren J et al (2015) Global HIV-1 transmitted drug resistance in the INSIGHT strategic timing of AntiRetroviral treatment (START) trial. HIV Med 16(Suppl 1):77\u201387","journal-title":"HIV Med"},{"key":"2_CR34","volume-title":"HIV drug resistance report 2019","author":"WHO","year":"2019","unstructured":"WHO (2019) HIV drug resistance report 2019. World Health Organization, Geneva"},{"key":"2_CR35","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/jac\/dkaa100","volume":"75","author":"A Gir\u00f3n-Callejas","year":"2020","unstructured":"Gir\u00f3n-Callejas A, Garc\u00eda-Morales C, Mendizabal-Burastero R, Meza RI, Sierra T, Tapia-Trejo D, P\u00e9rez-Garc\u00eda M, Quiroz-Morales VS, Paredes M, Rodr\u00edguez A et al (2020) High level of pre-treatment and acquired HIV drug resistance in Honduras: a nationally representative survey, 2016-17. J Antimicrob Chemother 75:1932\u20131942","journal-title":"J Antimicrob Chemother"},{"key":"2_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40249-019-0573-1","volume":"8","author":"E Ndashimye","year":"2019","unstructured":"Ndashimye E, Arts EJ (2019) The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. Infect Dis Poverty 8:63","journal-title":"Infect Dis Poverty"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1089\/aid.2019.0063","volume":"35","author":"RM Kagan","year":"2019","unstructured":"Kagan RM, Dunn KJ, Snell GP, Nettles RE, Kaufman HW (2019) Trends in HIV-1 drug resistance mutations from a U.S. reference laboratory from 2006 to 2017. AIDS Res Hum Retrovir 35:698\u2013709","journal-title":"AIDS Res Hum Retrovir"},{"key":"2_CR38","first-page":"100238","volume":"18","author":"L Zuo","year":"2020","unstructured":"Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J, Xu Q, Peng K, Jin X, Wang JH et al (2020) Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001-2017). E Clin Med 18:100238","journal-title":"E Clin Med"},{"key":"2_CR39","doi-asserted-by":"crossref","first-page":"1800390","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800390","volume":"24","author":"MJ van de Laar","year":"2019","unstructured":"van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML et al (2019) Piloting a surveillance system for HIV drug resistance in the European Union. Euro Surveill 24:1800390","journal-title":"Euro Surveill"},{"key":"2_CR40","doi-asserted-by":"crossref","unstructured":"Ma Y, Frutos-Beltr\u00e1n E, Kang D, Pannecouque C, De Clercq E, Men\u00e9ndez-Arias L, Liu X, Zhan P (2021) Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 50:4514-4540","DOI":"10.1039\/D0CS01084G"},{"key":"2_CR41","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","volume":"7","author":"D Sch\u00fcrmann","year":"2020","unstructured":"Sch\u00fcrmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, H\u00fcser A, Hofmann J, Grobler JA et al (2020) Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV 7:e164\u2013e172","journal-title":"Lancet HIV"},{"key":"2_CR42","doi-asserted-by":"crossref","unstructured":"Barrett SE, Teller RS, Forster SP, Li L, Mackey MA, Skomski D, Yang Z, Fillgrove KL, Doto GJ, Wood SL et al (2018) Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother 62:e01058\u201318","DOI":"10.1128\/AAC.01058-18"},{"key":"2_CR43","doi-asserted-by":"publisher","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","volume":"289","author":"E Michailidis","year":"2014","unstructured":"Michailidis E, Huber AD, Ryan EM, Ong YT, Leslie MD, Matzek KB, Singh K, Marchand B, Hagedorn AN, Kirby KA et al (2014) 4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem 289:24533\u201324548","journal-title":"J Biol Chem"},{"key":"2_CR44","doi-asserted-by":"publisher","first-page":"9274","DOI":"10.1073\/pnas.1605223113","volume":"113","author":"ZL Salie","year":"2016","unstructured":"Salie ZL, Kirby KA, Michailidis E, Marchand B, Singh K, Rohan LC, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG (2016) Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA). Proc Natl Acad Sci U S A 113:9274\u20139279","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2_CR45","unstructured":"Molina J-M, Yarzdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, DeJesus E, Klopfer SO, Eves K, Robertson MN, Hwang C et al (2019) Tolerability, safety, and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD in combination with doravirine and lamivudine through 24 weeks in treatment-naive adults with HIV-1 infection. In: Proceedings of the 10th IAS conference on HIV science (IAS 2019); 21\u201324 July 2019; Mexico City, Mexico"},{"key":"2_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/COH.0000000000000599","volume":"15","author":"M Markowitz","year":"2020","unstructured":"Markowitz M, Grobler JA (2020) Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Curr Opin HIV AIDS 15:27\u201332","journal-title":"Curr Opin HIV AIDS"},{"key":"2_CR47","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","volume":"40","author":"A Kawamoto","year":"2008","unstructured":"Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H et al (2008) 2\u2032-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 40:2410\u20132420","journal-title":"Int J Biochem Cell Biol"},{"key":"2_CR48","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1128\/AAC.00686-09","volume":"53","author":"G Yang","year":"2009","unstructured":"Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC (2009) Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4\u2032-ethynylthymidine analog resistance profile. Antimicrob Agents Chemother 53:4640\u20134646","journal-title":"Antimicrob Agents Chemother"},{"key":"2_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","volume":"222","author":"J Gregson","year":"2020","unstructured":"Gregson J, Rhee SY, Datir R, Pillay D, Perno CF, Derache A, Shafer RS, Gupta RK (2020) Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V\/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I. J Infect Dis 222:1108\u20131116","journal-title":"J Infect Dis"},{"key":"2_CR50","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1128\/AAC.01215-07","volume":"52","author":"T Cihlar","year":"2008","unstructured":"Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F et al (2008) Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 52:655\u2013665","journal-title":"Antimicrob Agents Chemother"},{"key":"2_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","volume":"58","author":"A Boyle","year":"2019","unstructured":"Boyle A, Moss CE, Marzolini C, Khoo S (2019) Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet 58:1553\u20131565","journal-title":"Clin Pharmacokinet"},{"key":"2_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1021\/acsinfecdis.9b00178","volume":"6","author":"C Hwang","year":"2020","unstructured":"Hwang C, Lai MT, Hazuda D (2020) Rational design of doravirine: from bench to patients. ACS Infect Dis 6:64\u201373","journal-title":"ACS Infect Dis"},{"key":"2_CR53","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s40265-017-0820-3","volume":"77","author":"ZT Al-Salama","year":"2017","unstructured":"Al-Salama ZT (2017) Elsulfavirine: first global approval. Drugs 77:1811\u20131816","journal-title":"Drugs"},{"key":"2_CR54","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/ml5003713","volume":"5","author":"WG Lee","year":"2014","unstructured":"Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Bollini M, Anderson KS, Jorgensen WL (2014) Picomolar inhibitors of HIV-1 reverse transcriptase: design and crystallography of naphthyl phenyl ethers. ACS Med Chem Lett 5:1259\u20131262","journal-title":"ACS Med Chem Lett"},{"key":"2_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang Y, De Clercq E, Li G (2019) Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin Drug Metab Toxicol 15:813\u2013829","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2_CR56","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","volume":"74","author":"SY Rhee","year":"2019","unstructured":"Rhee SY, Grant PM, Tzou PL, Barrow G, Harrigan PR, Ioannidis JPA, Shafer RW (2019) A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother 74:3135\u20133149","journal-title":"J Antimicrob Chemother"},{"key":"2_CR57","doi-asserted-by":"crossref","unstructured":"Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH (2018) Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 15:37","DOI":"10.1186\/s12977-018-0420-7"},{"key":"2_CR58","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM et al (2016) Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 60:7086\u20137097","journal-title":"Antimicrob Agents Chemother"},{"key":"2_CR59","doi-asserted-by":"crossref","unstructured":"Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, Vicenti I, Zazzi M (2019) Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations. Antimicrob Agents Chemother 64:e01717\u201319","DOI":"10.1128\/AAC.01717-19"},{"key":"2_CR60","doi-asserted-by":"crossref","unstructured":"Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR Jr, Hughes SH (2020) HIV-1 integrase inhibitors that are active against drug-resistant integrase mutants. Antimicrob Agents Chemother 64:00611\u201320","DOI":"10.1128\/AAC.00611-20"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aay4919","volume":"367","author":"NJ Cook","year":"2020","unstructured":"Cook NJ, Li W, Berta D, Badaoui M, Ballandras-Colas A, Nans A, Kotecha A, Rosta E, Engelman AN, Cherepanov P (2020) Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science 367:806\u2013810","journal-title":"Science"},{"key":"2_CR62","first-page":"157","volume":"8","author":"T Whitfield","year":"2016","unstructured":"Whitfield T, Torkington A, van Halsema C (2016) Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS (Auckl) 8:157\u2013164","journal-title":"HIV AIDS (Auckl)"},{"key":"2_CR63","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, Latiff G, Pokrovsky V, Bredeek F, Smith G et al (2020) Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 382:1112\u20131123","journal-title":"N Engl J Med"},{"key":"2_CR64","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","volume":"19","author":"TA Kulkarni","year":"2020","unstructured":"Kulkarni TA, Bade AN, Sillman B, Shetty BLD, Wojtkiewicz MS, Gautam N, Hilaire JR, Sravanam S, Szlachetka A, Lamberty BG et al (2020) A year-long extended release nanoformulated cabotegravir prodrug. Nat Mater 19:910\u2013920","journal-title":"Nat Mater"},{"key":"2_CR65","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40265-020-01326-8","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Cabotegravir plus rilpivirine: first approval. Drugs 80:915\u2013922","journal-title":"Drugs"},{"key":"2_CR66","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/cid\/ciy653","volume":"68","author":"CJ Hoesley","year":"2019","unstructured":"Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Bauermeister J, Hall W, Jacobson C et al (2019) Phase 1 safety and pharmacokinetics study of MK-2048\/vicriviroc (MK-4176)\/MK-2048A intravaginal rings. Clin Infect Dis 68:1136\u20131143","journal-title":"Clin Infect Dis"},{"key":"2_CR67","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/cid\/ciy652","volume":"68","author":"AY Liu","year":"2019","unstructured":"Liu AY, Zhang J, Anderson PL, Wagner T, Pan Z, Peda M, Gomez K, Beamer M, Jacobson C, Strizki J et al (2019) Phase 1 pharmacokinetic trial of 2 intravaginal rings containing different dose strengths of vicriviroc (MK-4176) and MK-2048. Clin Infect Dis 68:1129\u20131135","journal-title":"Clin Infect Dis"},{"key":"2_CR68","doi-asserted-by":"crossref","unstructured":"Nakamura T, Nakamura T, Amano M, Miyakawa T, Yamagata Y, Matsuoka M, Nakata H (2020) A conformational escape reaction of HIV-1 against an allosteric integrase inhibitor. J Virol 94:e00486\u201320","DOI":"10.1128\/JVI.00486-20"},{"key":"2_CR69","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"AK Ghosh","year":"2016","unstructured":"Ghosh AK, Osswald HL, Prato G (2016) Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J Med Chem 59:5172\u20135208","journal-title":"J Med Chem"},{"key":"2_CR70","doi-asserted-by":"publisher","first-page":"10664","DOI":"10.1038\/s41598-020-65993-z","volume":"10","author":"H Bulut","year":"2020","unstructured":"Bulut H, Hattori SI, Aoki-Ogata H, Hayashi H, Das D, Aoki M, Davis DA, Rao KV, Nyalapatla PR, Ghosh AK et al (2020) Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Sci Rep 10:10664","journal-title":"Sci Rep"},{"key":"2_CR71","doi-asserted-by":"crossref","unstructured":"Hattori SI, Hayashi H, Bulut H, Rao KV, Nyalapatla PR, Hasegawa K, Aoki M, Ghosh AK, Mitsuya H (2019) Halogen bond interactions of novel HIV-1 protease inhibitors (PI) (GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type HIV-1 and multi-PI-resistant variants. Antimicrob Agents Chemother 63:e02635\u201318","DOI":"10.1128\/AAC.02635-18"},{"key":"2_CR72","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1021\/acs.jmedchem.9b00002","volume":"62","author":"MAM Subbaiah","year":"2019","unstructured":"Subbaiah MAM, Mandlekar S, Desikan S, Ramar T, Subramani L, Annadurai M, Desai SD, Sinha S, Jenkins SM, Krystal MR et al (2019) Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir. J Med Chem 62:3553\u20133574","journal-title":"J Med Chem"},{"key":"2_CR73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1021\/acs.molpharmaceut.9b00871","volume":"17","author":"MG Banoub","year":"2020","unstructured":"Banoub MG, Bade AN, Lin Z, Cobb D, Gautam N, Dyavar Shetty BL, Wojtkiewicz M, Alnouti Y, McMillan J, Gendelman HE et al (2020) Synthesis and characterization of long-acting darunavir prodrugs. Mol Pharm 17:155\u2013166","journal-title":"Mol Pharm"},{"key":"2_CR74","doi-asserted-by":"publisher","first-page":"104544","DOI":"10.1016\/j.antiviral.2019.104544","volume":"169","author":"DW Zhang","year":"2019","unstructured":"Zhang DW, Luo RH, Xu L, Yang LM, Xu XS, Bedwell GJ, Engelman AN, Zheng YT, Chang S (2019) A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-terminal domain of capsid. Antiviral Res 169:104544","journal-title":"Antiviral Res"},{"key":"2_CR75","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1128\/JVI.01406-10","volume":"85","author":"J Shi","year":"2011","unstructured":"Shi J, Zhou J, Shah VB, Aiken C, Whitby K (2011) Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85:542\u2013549","journal-title":"J Virol"},{"key":"2_CR76","doi-asserted-by":"publisher","first-page":"e1004459","DOI":"10.1371\/journal.ppat.1004459","volume":"10","author":"AJ Price","year":"2014","unstructured":"Price AJ, Jacques DA, McEwan WA, Fletcher AJ, Essig S, Chin JW, Halambage UD, Aiken C, James LC (2014) Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog 10:e1004459","journal-title":"PLoS Pathog"},{"key":"2_CR77","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.3390\/diseases7040056","volume":"7","author":"C McArthur","year":"2019","unstructured":"McArthur C, Gallazzi F, Quinn TP, Singh K (2019) HIV capsid inhibitors beyond PF74. Diseases 7:e56","journal-title":"Diseases"},{"key":"2_CR78","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, Begley R, Chiu A, Mulato A, Hansen D et al (2020) Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584:614\u2013618","journal-title":"Nature"},{"key":"2_CR79","doi-asserted-by":"publisher","first-page":"10286","DOI":"10.1073\/pnas.1917755117","volume":"117","author":"S Gupta","year":"2020","unstructured":"Gupta S, Louis JM, Tycko R (2020) Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles. Proc Natl Acad Sci U S A 117:10286\u201310293","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2_CR80","doi-asserted-by":"publisher","first-page":"12095","DOI":"10.1128\/JVI.01626-06","volume":"80","author":"J Zhou","year":"2006","unstructured":"Zhou J, Chen CH, Aiken C (2006) Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3\u2032,3\u2032-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 80:12095\u201312101","journal-title":"J Virol"},{"key":"2_CR81","doi-asserted-by":"publisher","first-page":"e0205368","DOI":"10.1371\/journal.pone.0205368","volume":"13","author":"J Morales-Ramirez","year":"2018","unstructured":"Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, DeGrosky M, Gartland M, Pene Dumitrescu T, Min S et al (2018) Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir\/emtricitabine once daily in treatment-naive HIV-1-infected adults: week 24 primary analysis from a randomized phase IIb trial. PLoS One 13:e0205368","journal-title":"PLoS One"},{"key":"2_CR82","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciz938","volume":"71","author":"E DeJesus","year":"2020","unstructured":"DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J et al (2020) A phase IIa study evaluating safety, pharmacokinetics, and antiviral activity of GSK2838232, a novel, second-generation maturation inhibitor, in participants with human immunodeficiency virus type 1 infection. Clin Infect Dis 71:1255\u20131262","journal-title":"Clin Infect Dis"},{"key":"2_CR83","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","volume":"61","author":"NA Meanwell","year":"2018","unstructured":"Meanwell NA, Krystal MR, Nowicka-Sans B, Langley DR, Conlon DA, Eastgate MD, Grasela DM, Timmins P, Wang T, Kadow JF (2018) Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir. J Med Chem 61:62\u201380","journal-title":"J Med Chem"},{"key":"2_CR84","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P et al (2020) Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med 382:1232\u20131243","journal-title":"N Engl J Med"},{"key":"2_CR85","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ejmech.2014.09.012","volume":"86","author":"T Liu","year":"2014","unstructured":"Liu T, Huang B, Zhan P, De Clercq E, Liu X (2014) Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806. Eur J Med Chem 86:481\u2013490","journal-title":"Eur J Med Chem"},{"key":"2_CR86","doi-asserted-by":"crossref","unstructured":"Zou S, Zhang S, Gaffney A, Ding H, Lu M, Grover JR, Farrell M, Nguyen HT, Zhao C, Anang S et al (2020) Long-acting BMS-378806 analogues stabilize the state-1 conformation of the human immunodeficiency virus type 1 envelope glycoproteins. J Virol 94:e00148\u201320","DOI":"10.1128\/JVI.00148-20"},{"key":"2_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","volume":"62","author":"CS Pace","year":"2013","unstructured":"Pace CS, Fordyce MW, Franco D, Kao C-Y, Seaman MS, Ho DD (2013) Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 62:1\u20139","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2_CR88","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cao W, Sun M, Li T (2020) Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect 9:194\u2013206","journal-title":"Emerg Microbes Infect"},{"key":"2_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7514","volume":"9","author":"M Bonsignori","year":"2017","unstructured":"Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK et al (2017) Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med 9:eaai7514","journal-title":"Sci Transl Med"},{"key":"2_CR90","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMp1613362","volume":"375","author":"M Caskey","year":"2016","unstructured":"Caskey M, Klein F, Nussenzweig MC (2016) Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N Engl J Med 375:2019\u20132021","journal-title":"N Engl J Med"},{"key":"2_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","volume":"275","author":"LE McCoy","year":"2017","unstructured":"McCoy LE, Burton DR (2017) Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev 275:11\u201320","journal-title":"Immunol Rev"},{"key":"2_CR92","doi-asserted-by":"crossref","unstructured":"Wang H, Gristick HB, Scharf L, West AP, Galimidi RP, Seaman MS, Freund NT, Nussenzweig MC, Bjorkman PJ (2017) Asymmetric recognition of HIV-1 envelope trimer by V1V2 loop-targeting antibodies. Elife 6:e27389","DOI":"10.7554\/eLife.27389"},{"key":"2_CR93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al (2017) Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med 23:185\u2013191","journal-title":"Nat Med"},{"key":"2_CR94","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS et al (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206","journal-title":"Sci Transl Med"},{"key":"2_CR95","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1172\/JCI134395","volume":"130","author":"EM Cale","year":"2020","unstructured":"Cale EM, Bai H, Bose M, Messina MA, Colby DJ, Sanders-Buell E, Dearlove B, Li Y, Engeman E, Silas D et al (2020) Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J Clin Invest 130:3299\u20133304","journal-title":"J Clin Invest"},{"key":"2_CR96","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12977-018-0439-9","volume":"15","author":"NN Padte","year":"2018","unstructured":"Padte NN, Yu J, Huang Y, Ho DD (2018) Engineering multi-specific antibodies against HIV-1. Retrovirology 15:60","journal-title":"Retrovirology"},{"key":"2_CR97","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","volume":"19","author":"K Dhody","year":"2018","unstructured":"Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ (2018) PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials 19:85\u201393","journal-title":"HIV Clin Trials"},{"key":"2_CR98","doi-asserted-by":"publisher","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","volume":"12","author":"H Kaplon","year":"2020","unstructured":"Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020) Antibodies to watch in 2020. MAbs 12:1703531","journal-title":"MAbs"},{"key":"2_CR99","doi-asserted-by":"publisher","DOI":"10.1177\/2040206619829382","volume":"27","author":"E De Clercq","year":"2019","unstructured":"De Clercq E (2019) Mozobil\u00ae (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem Chemother 27:2040206619829382","journal-title":"Antivir Chem Chemother"},{"key":"2_CR100","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3324\/haematol.2017.184788","volume":"103","author":"C Lagresle-Peyrou","year":"2018","unstructured":"Lagresle-Peyrou C, Lefr\u00e8re F, Magrin E, Ribeil JA, Romano O, Weber L, Magnani A, Sadek H, Plantier C, Gabrion A et al (2018) Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica 103:778\u2013786","journal-title":"Haematologica"},{"key":"2_CR101","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.phrs.2020.105010","volume":"159","author":"J Wang","year":"2020","unstructured":"Wang J, Tannous BA, Poznansky MC, Chen H (2020) CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent. Pharmacol Res 159:105010","journal-title":"Pharmacol Res"},{"key":"2_CR102","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/1535370220901498","volume":"245","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhu R, Cao Q, Yang X, Huang Z, An J (2020) Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors. Exp Biol Med (Maywood) 245:477\u2013485","journal-title":"Exp Biol Med (Maywood)"},{"key":"2_CR103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","volume":"13","author":"H Zhang","year":"2016","unstructured":"Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, Peng H, Wang X, Lu R, Wang C et al (2016) Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients. AIDS Res Ther 13:8","journal-title":"AIDS Res Ther"},{"key":"2_CR104","doi-asserted-by":"publisher","first-page":"104613","DOI":"10.1016\/j.antiviral.2019.104613","volume":"171","author":"E Tramontano","year":"2019","unstructured":"Tramontano E, Corona A, Men\u00e9ndez-Arias L (2019) Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus. Antiviral Res 171:104613","journal-title":"Antiviral Res"},{"key":"2_CR105","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2174\/0929867324666170113110839","volume":"25","author":"X Wang","year":"2018","unstructured":"Wang X, Gao P, Men\u00e9ndez-Arias L, Liu X, Zhan P (2018) Update on recent developments in small molecular HIV-1 RNase H inhibitors (2013-2016): opportunities and challenges. Curr Med Chem 25:1682\u20131702","journal-title":"Curr Med Chem"},{"key":"2_CR106","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2019.06.058","volume":"179","author":"MSA Gill","year":"2019","unstructured":"Gill MSA, Hassan SS, Ahemad N (2019) Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: recent advances and developments. Eur J Med Chem 179:423\u2013448","journal-title":"Eur J Med Chem"},{"key":"2_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147225","volume":"11","author":"A Corona","year":"2016","unstructured":"Corona A, Meleddu R, Esposito F, Distinto S, Bianco G, Masaoka T, Maccioni E, Men\u00e9ndez-Arias L, Alcaro S, Le Grice SF et al (2016) Ribonuclease H\/DNA polymerase HIV-1 reverse transcriptase dual inhibitor: mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6. PLoS One 11:e0147225","journal-title":"PLoS One"},{"key":"2_CR108","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1038\/emi.2017.26","volume":"6","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zhu J, Hassink M, Jenkins LMM, Wan Y, Appella DH, Xu J, Appella E, Zhang X (2017) A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins. Emerg Microbes Infect 6:e40","journal-title":"Emerg Microbes Infect"},{"key":"2_CR109","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.drudis.2018.01.022","volume":"23","author":"N Iraci","year":"2018","unstructured":"Iraci N, Tabarrini O, Santi C, Sancineto L (2018) NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders. Drug Discov Today 23:687\u2013695","journal-title":"Drug Discov Today"},{"key":"2_CR110","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.drudis.2017.10.017","volume":"23","author":"L Sancineto","year":"2018","unstructured":"Sancineto L, Iraci N, Tabarrini O, Santi C (2018) NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors. Drug Discov Today 23:260\u2013271","journal-title":"Drug Discov Today"},{"key":"2_CR111","doi-asserted-by":"publisher","first-page":"112111","DOI":"10.1016\/j.ejmech.2020.112111","volume":"190","author":"TJ Rashamuse","year":"2020","unstructured":"Rashamuse TJ, Njengele Z, Coyanis EM, Sayed Y, Mosebi S, Bode ML (2020) Design, synthesis and biological evaluation of novel 2-(5-aryl-1H-imidazol-1-yl) derivatives as potential inhibitors of the HIV-1 Vpu and host BST-2 protein interaction. Eur J Med Chem 190:112111","journal-title":"Eur J Med Chem"},{"key":"2_CR112","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/pro.3729","volume":"29","author":"FC Azimi","year":"2020","unstructured":"Azimi FC, Lee JE (2020) Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions. Protein Sci 29:391\u2013406","journal-title":"Protein Sci"},{"key":"2_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","volume":"316","author":"AJ Rodger","year":"2016","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A et al (2016) Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316:171\u2013181. Erratum in: JAMA (2016) 316:667. Erratum in: JAMA (2016) 316:2048","journal-title":"JAMA"},{"key":"2_CR114","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A et al (2019) Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 393:2428\u20132438","journal-title":"Lancet"},{"key":"2_CR115","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/cid\/ciz998","volume":"69","author":"RW Eisinger","year":"2019","unstructured":"Eisinger RW, Folkers GK, Fauci AS (2019) Ending the human immunodeficiency virus pandemic: optimizing the prevention and treatment toolkits. Clin Infect Dis 69:2212\u20132217","journal-title":"Clin Infect Dis"},{"key":"2_CR116","doi-asserted-by":"publisher","first-page":"e1002132","DOI":"10.1371\/journal.pmed.1002132","volume":"13","author":"KK Mugwanya","year":"2016","unstructured":"Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, Semiyaga NB, John-Stewart G, Muwonge TR, Muthuri G et al (2016) Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 13:e1002132","journal-title":"PLoS Med"},{"key":"2_CR117","volume-title":"Preventing HIV during pregnancy and breastfeeding in the context of PrEP - technical brief","author":"WHO","year":"2017","unstructured":"WHO (2017) Preventing HIV during pregnancy and breastfeeding in the context of PrEP - technical brief. World Health Organization, Geneva"},{"key":"2_CR118","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F et al (2016) Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 375:2121\u20132132","journal-title":"N Engl J Med"},{"key":"2_CR119","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, Kamali A, Kotze P, Louw C, Mabude Z et al (2016) Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med 375:2133\u20132143","journal-title":"N Engl J Med"},{"key":"2_CR120","doi-asserted-by":"crossref","unstructured":"Srinivas N, Cottrell M, Maffuid K, Prince HA, Nelson JAE, White N, Sykes C, Dellon ES, Madanick RD, Shaheen NJ et al (2020) Translational approach to predicting the efficacy of maraviroc-based regimens as HIV preexposure prophylaxis. Antimicrob Agents Chemother 64:e01729\u201319","DOI":"10.1128\/AAC.01729-19"},{"key":"2_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/COH.0000000000000591","volume":"15","author":"ED Weld","year":"2020","unstructured":"Weld ED, Flexner C (2020) Long-acting implants to treat and prevent HIV infection. Curr Opin HIV AIDS 15:33\u201341","journal-title":"Curr Opin HIV AIDS"},{"key":"2_CR122","doi-asserted-by":"publisher","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","volume":"15","author":"RJ Landovitz","year":"2018","unstructured":"Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G et al (2018) Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med 15:e1002690","journal-title":"PLoS Med"},{"key":"2_CR123","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","volume":"24","author":"R Gautam","year":"2018","unstructured":"Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC et al (2018) A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med 24:610\u2013616","journal-title":"Nat Med"},{"key":"2_CR124","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Su\u00e1rez I, Oliveira TY et al (2018) Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24:1701\u20131707","journal-title":"Nat Med"},{"key":"2_CR125","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","volume":"80","author":"AI Rana","year":"2020","unstructured":"Rana AI, Castillo-Mancilla JR, Tashima KT, Landovitz RL (2020) Advances in long-acting agents for the treatment of HIV infection. Drugs 80:535\u2013545","journal-title":"Drugs"},{"key":"2_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020062","volume":"12","author":"K Singh","year":"2019","unstructured":"Singh K, Sarafianos SG, S\u00f6nnerborg A (2019) Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase. Pharmaceuticals (Basel) 12:e62","journal-title":"Pharmaceuticals (Basel)"},{"key":"2_CR127","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","volume":"6","author":"M Aboud","year":"2019","unstructured":"Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA et al (2019) Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV 6:e576\u2013e587","journal-title":"Lancet HIV"},{"key":"2_CR128","unstructured":"Overton ET, Richmond GJ, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, Garc\u00eda-Deltoro M, Benn PD, Wang Y et al (2020) Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. In: Conference on retroviruses and opportunistic infections (CROI). March 8-11, 2020. Boston. Abstract 34"},{"key":"2_CR129","doi-asserted-by":"crossref","unstructured":"Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L et al (2020) Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7:e472-e481","DOI":"10.1016\/S2352-3018(20)30106-5"},{"key":"2_CR130","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, Nowak D, Mossner M, Ganepola S, M\u00fcssig A, Allers K, Schneider T, Hofmann J, K\u00fccherer C, Blau O et al (2009) Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med 360:692\u2013698","journal-title":"N Engl J Med"},{"key":"2_CR131","doi-asserted-by":"publisher","first-page":"e1003347","DOI":"10.1371\/journal.ppat.1003347","volume":"9","author":"SA Yukl","year":"2013","unstructured":"Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, H\u00fctter G et al (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 9:e1003347","journal-title":"PLoS Pathog"},{"key":"2_CR132","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, Peppa D, Hill AL, G\u00e1lvez C, Salgado M, Pace M, McCoy LE, Griffith SA, Thornhill J, Alrubayyi A et al (2020) Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV 7:e340\u2013e347","journal-title":"Lancet HIV"},{"key":"2_CR133","unstructured":"Jensen B-E, Knops E, L\u00fcbke N, Wensing A, Martinez-Picado J, Kaiser R, Nijhuis M, Salgado M, Harrer T, Heger E, et al (2019) Analytic treatment interruption (ATI) after allogeneic CCR5-D32 HSCT for AML in 2013. In: Conference on retroviruses and opportunistic infections (CROI). March 4\u20137, 2019. Seattle, WA, Abstract 394"},{"key":"2_CR134","doi-asserted-by":"publisher","first-page":"102667","DOI":"10.1016\/j.ebiom.2020.102667","volume":"53","author":"PK Dash","year":"2020","unstructured":"Dash PK, Kevadiya BD, Su H, Banoub MG, Gendelman HE (2020) Pathways towards human immunodeficiency virus elimination. EBioMedicine 53:102667","journal-title":"EBioMedicine"},{"key":"2_CR135","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cell.2020.03.005","volume":"181","author":"DM Margolis","year":"2020","unstructured":"Margolis DM, Archin NM, Cohen MS, Eron JJ, Ferrari G, Garcia JV, Gay CL, Goonetilleke N, Joseph SB, Swanstrom R et al (2020) Curing HIV: seeking to target and clear persistent infection. Cell 181:189\u2013206","journal-title":"Cell"},{"key":"2_CR136","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","volume":"576","author":"T Ndung'u","year":"2019","unstructured":"Ndung'u T, McCune JM, Deeks SG (2019) Why and where an HIV cure is needed and how it might be achieved. Nature 576:397\u2013405","journal-title":"Nature"},{"key":"2_CR137","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s00018-019-03156-8","volume":"76","author":"I Sadowski","year":"2019","unstructured":"Sadowski I, Hashemi FB (2019) Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. Cell Mol Life Sci 76:3583\u20133600","journal-title":"Cell Mol Life Sci"},{"key":"2_CR138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2019.03.008","volume":"166","author":"E Abner","year":"2019","unstructured":"Abner E, Jordan A (2019) HIV \u201cshock and kill\u201d therapy: in need of revision. Antiviral Res 166:19\u201334","journal-title":"Antiviral Res"},{"key":"2_CR139","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","volume":"38","author":"G Darcis","year":"2017","unstructured":"Darcis G, Van Driessche B, Van Lint C (2017) HIV latency: should we shock or lock? Trends Immunol 38:217\u2013228","journal-title":"Trends Immunol"},{"key":"2_CR140","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.3390\/v12010084","volume":"12","author":"G Vansant","year":"2020","unstructured":"Vansant G, Bruggemans A, Janssens J, Debyser Z (2020) Block-and-lock strategies to cure HIV infection. Viruses 12:e84","journal-title":"Viruses"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:04:46Z","timestamp":1675566286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":140,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}